Journal Article

Exome sequencing identifies MXRA5 as a novel cancer gene frequently mutated in non–small cell lung carcinoma from Chinese patients

Donghai Xiong, Guangming Li, Kezhen Li, Qinzi Xu, Zhongjie Pan, Feng Ding, Peter Vedell, Pengyuan Liu, Peng Cui, Xing Hua, Hui Jiang, Yuxin Yin, Ze Zhu, Xiaomian Li, Bin Zhang, Ding Ma, Yian Wang and Ming You

in Carcinogenesis

Volume 33, issue 9, pages 1797-1805
Published in print September 2012 | ISSN: 0143-3334
Published online June 2012 | e-ISSN: 1460-2180 | DOI: https://dx.doi.org/10.1093/carcin/bgs210
Exome sequencing identifies MXRA5 as a novel cancer gene frequently mutated in non–small cell lung carcinoma from Chinese patients

More Like This

Show all results sharing this subject:

  • Clinical Cytogenetics and Molecular Genetics

GO

Show Summary Details

Preview

Lung cancer has become the top killer among malignant tumors in China and is significantly associated with somatic genetic alterations. We performed exome sequencing of 14 non–small cell lung carcinomas (NSCLCs) with matched adjacent normal lung tissues extracted from Chinese patients. In addition to the lung cancer–related genes (TP53, EGFR, KRAS, PIK3CA, and ROS1), this study revealed “novel” genes not previously implicated in NSCLC. Especially, matrix-remodeling associated 5 was the second most frequently mutated gene in NSCLC (first is TP53). Subsequent Sanger sequencing of matrix-remodeling associated 5 in an additional sample set consisting of 52 paired tumor-normal DNA samples revealed that 15% of Chinese NSCLCs contained somatic mutations in matrix-remodeling associated 5. These findings, together with the results from pathway analysis, strongly indicate that altered extracellular matrix-remodeling may be involved in the etiology of NSCLC.

Journal Article.  6277 words.  Illustrated.

Subjects: Clinical Cytogenetics and Molecular Genetics

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.